• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TAVR in Low-Risk Patients: FDA Approval, the New NCD, and Shared Decision-Making.

作者信息

Coylewright Megan, Forrest John K, McCabe James M, Nazif Tamim M

机构信息

Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.

出版信息

J Am Coll Cardiol. 2020 Mar 17;75(10):1208-1211. doi: 10.1016/j.jacc.2019.12.057.

DOI:10.1016/j.jacc.2019.12.057
PMID:32164894
Abstract
摘要

相似文献

1
TAVR in Low-Risk Patients: FDA Approval, the New NCD, and Shared Decision-Making.低风险患者的经导管主动脉瓣置换术：美国食品药品监督管理局的批准、新的国家医保覆盖决策以及共同决策制定
J Am Coll Cardiol. 2020 Mar 17;75(10):1208-1211. doi: 10.1016/j.jacc.2019.12.057.
2
Transcatheter Aortic Valve Replacement for Patients at Low Surgical Risk-Selective or Ubiquitous?低手术风险患者的经导管主动脉瓣置换术——是选择性的还是普遍适用的？
JAMA Cardiol. 2020 Jan 1;5(1):7-8. doi: 10.1001/jamacardio.2019.4386.
3
The March of Transcatheter Aortic Valve Replacement Therapy-US Food and Drug Administration Perspectives on Device Approval for Patients at Low Surgical Risk.经导管主动脉瓣置换术治疗进展——美国食品药品监督管理局对低手术风险患者器械审批的观点
JAMA Cardiol. 2020 Jan 1;5(1):5-6. doi: 10.1001/jamacardio.2019.4383.
4
Is it time to refresh the heart team? New paradigms for shared decision making.是时候更新心脏团队了吗？共享决策的新范式。
Heart. 2021 Apr;107(8):674-681. doi: 10.1136/heartjnl-2020-316588. Epub 2020 Oct 27.
5
Long-term outlook for transcatheter aortic valve replacement.经导管主动脉瓣置换术的长期预后。
Trends Cardiovasc Med. 2018 Apr;28(3):174-183. doi: 10.1016/j.tcm.2017.08.004. Epub 2017 Aug 10.
6
CardioPulse: Transcatheter aortic valve replacement.The American perspective on transcatheter aortic valve replacement.《心脏脉搏：经导管主动脉瓣置换术。美国对经导管主动脉瓣置换术的观点》
Eur Heart J. 2016 Mar 7;37(10):797-9.
7
Utilization and outcomes of transcatheter aortic valve replacement in the United States shortly after device approval.在美国，经导管主动脉瓣置换术在设备获批后不久的应用情况及治疗效果。
Catheter Cardiovasc Interv. 2017 Nov 1;90(5):830-838. doi: 10.1002/ccd.27018. Epub 2017 Mar 22.
8
Considerations and Recommendations for the Introduction of Objective Performance Criteria for Transcatheter Aortic Heart Valve Device Approval.经导管主动脉心脏瓣膜装置批准引入客观性能标准的考量与建议。
Circulation. 2016 May 24;133(21):2086-93. doi: 10.1161/CIRCULATIONAHA.115.020493.
9
Two-year survival of patients screened for transcatheter aortic valve replacement with potentially malignant incidental findings in initial body computed tomography.在初次胸部计算机断层扫描中发现潜在恶性偶然病变的经导管主动脉瓣置换术筛查患者的两年生存率
Eur Heart J Cardiovasc Imaging. 2015 Jul;16(7):731-7. doi: 10.1093/ehjci/jev055. Epub 2015 Mar 10.
10
Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis.经导管主动脉瓣置换术治疗有症状的低危重度主动脉瓣狭窄患者。
J Am Coll Cardiol. 2018 Oct 30;72(18):2095-2105. doi: 10.1016/j.jacc.2018.08.1033. Epub 2018 Aug 28.

引用本文的文献

1
Management of complications after valvular interventions.瓣膜介入术后并发症的管理。
EuroIntervention. 2025 Apr 21;21(8):e390-e410. doi: 10.4244/EIJ-D-24-00066.
2
Validation of Medicare Advantage Claims for Long-Term Outcome Assessment in Low-Risk Aortic Valve Replacement.医疗保险优待计划用于低风险主动脉瓣置换术长期结果评估的索赔验证
Circ Cardiovasc Qual Outcomes. 2025 May;18(5):e011991. doi: 10.1161/CIRCOUTCOMES.125.011991. Epub 2025 Mar 29.
3
Paravalvular Leak After Transcatheter Aortic Valve Implantation: Results From 3600 Patients.
经导管主动脉瓣植入术后瓣周漏：3600例患者的结果
Ann Thorac Surg. 2025 May;119(5):1037-1044. doi: 10.1016/j.athoracsur.2025.01.012. Epub 2025 Jan 31.
4
Inequities in Access to Tricuspid Valve Treatments: The Impact of Procedure and Volume Requirements.三尖瓣治疗可及性的不平等：手术和容量要求的影响。
JACC Adv. 2024 Oct 18;3(11):101342. doi: 10.1016/j.jacadv.2024.101342. eCollection 2024 Nov.
5
The Promise and Perils of Transcatheter Aortic Valve Replacement (TAVR) in Low Surgical Risk Patients with Severe Aortic Stenosis in the Current Era.当代低手术风险重度主动脉瓣狭窄患者经导管主动脉瓣置换术（TAVR）的前景与风险
Curr Cardiol Rep. 2024 Nov;26(11):1173-1182. doi: 10.1007/s11886-024-02116-4. Epub 2024 Aug 16.
6
Obesity Paradox in Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术中的肥胖悖论。
Curr Cardiol Rep. 2024 Sep;26(9):1005-1009. doi: 10.1007/s11886-024-02098-3. Epub 2024 Jul 29.
7
Shared decision-making in the management of pulmonary nodules: a systematic review of quantitative and qualitative studies.肺结节管理中的共同决策：定量和定性研究的系统评价。
BMJ Open. 2024 Jul 11;14(7):e079080. doi: 10.1136/bmjopen-2023-079080.
8
Transcatheter Aortic Valve Replacement for Failed Surgical or Transcatheter Bioprosthetic Valves: A Comprehensive Review.经导管主动脉瓣置换术治疗外科手术或经导管生物人工瓣膜功能障碍：综述
J Clin Med. 2024 Feb 25;13(5):1297. doi: 10.3390/jcm13051297.
9
Bioprosthetic Valves for Lifetime Management of Aortic Stenosis: Pearls and Pitfalls.用于主动脉瓣狭窄终身管理的生物人工瓣膜：要点与陷阱
J Clin Med. 2023 Nov 13;12(22):7063. doi: 10.3390/jcm12227063.
10
Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR.首例仿生经导管主动脉瓣置换术的早期安全性和可行性 - DurAVR。
EuroIntervention. 2023 Jul 17;19(4):e352-e362. doi: 10.4244/EIJ-D-23-00282.